XBRL Proof

XBRL File

Document - Document and Entity Information

Document - Document and Entity Information (USD $)	9 Months Ended
( custom:DocumentAndEntityInformationAbstract [Extension] )
	Sep. 30, 2015	Nov. 3, 2015



Entity Registrant Name	Artventive Medical Group, Inc.
( dei:EntityRegistrantName )
Entity Central Index Key	0001405249
( dei:EntityCentralIndexKey )
Document Type	10-Q
( dei:DocumentType )
Document Period End Date	2015-09-30
( dei:DocumentPeriodEndDate )
Amendment Flag	false
( dei:AmendmentFlag )
Current Fiscal Year End Date	--12-31
( dei:CurrentFiscalYearEndDate )
Is Entity a Well-known Seasoned Issuer?	No
( dei:EntityWellKnownSeasonedIssuer )
Is Entity a Voluntary Filer?	No
( dei:EntityVoluntaryFilers )
Is Entity's Reporting Status Current?	Yes
( dei:EntityCurrentReportingStatus )
Entity Filer Category	Smaller Reporting Company
( dei:EntityFilerCategory )
Entity Public Float
( dei:EntityPublicFloat )
Entity Common Stock, Shares Outstanding		6,334,208
( dei:EntityCommonStockSharesOutstanding )		6334208
Document Fiscal Period Focus	Q3
( dei:DocumentFiscalPeriodFocus )
Document Fiscal Year Focus	2015
( dei:DocumentFiscalYearFocus )

(End Document - Document and Entity Information)

Statement - Balance Sheets (Unaudited)

Statement - Balance Sheets (Unaudited) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Sep. 30, 2015		Dec. 31, 2014





Assets
( us-gaap:AssetsAbstract )
current
( us-gaap:AssetsCurrentAbstract )
Cash and cash equivalents	53,005		104,030
( us-gaap:CashAndCashEquivalentsAtCarryingValue )	53005		104030
Accounts receivable	57,297		22,662
( us-gaap:AccountsReceivableNet )	57297		22662
Prepaid expenses	1,048		1,048
( us-gaap:PrepaidExpenseCurrent )	1048		1048
Inventory	304,415		23,738
( us-gaap:InventoryGross )	304415		23738
Total current assets	415,765		151,478
( us-gaap:AssetsCurrent )	415765		151478
PROPERTY, PLANT and equipment
( us-gaap:PropertyPlantAndEquipmentAbstract )
Office equipment	23,802		17,953
( us-gaap:PropertyPlantAndEquipmentOther )	23802		17953
Accumulated depreciation	(8,804	)	(5,467	)
( us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment )	-8804		-5467
net property, plant and equipment	14,998		12,486
( us-gaap:PropertyPlantAndEquipmentNet )	14998		12486
other assets
( us-gaap:OtherAssetsAbstract )
Deposits	115,182		25,007
( us-gaap:Deposits )	115182		25007
total other assets	115,182		25,007
( us-gaap:OtherAssets )	115182		25007


Total assets	545,945		188,971
( us-gaap:Assets )	545945		188971


Liabilities and stockholders’ EQUITY
( us-gaap:LiabilitiesAndStockholdersEquityAbstract )
current LIABILITES
( us-gaap:LiabilitiesCurrentAbstract )
Accounts payable	603,805		221,397
( us-gaap:AccountsPayableCurrent )	603805		221397
Accrued expenses	�		1,043,300
( us-gaap:AccruedLiabilitiesCurrent )			1043300
Payroll taxes payable	61		�
( us-gaap:AccruedPayrollTaxesCurrent )	61
Total CURRENT liabilities	603,866		1,264,697
( us-gaap:LiabilitiesCurrent )	603866		1264697


LONG-TERM LIABILITES
( us-gaap:LongTermDebtAbstract )
Notes payable	500,000		500,000
( us-gaap:NotesPayable )	500000		500000
Total LONG-TERM liabilities	500,000		500,000
( us-gaap:LongTermDebtNoncurrent )	500000		500000


Total LIABILITIES	1,103,866		1,764,697
( us-gaap:AccruedLiabilitiesCurrentAndNoncurrent )	1103866		1764697






stockholders’ EQUITY (deficit)
( us-gaap:EquityAbstract )


Common stock, par value $.001, 100,000,000 shares authorized, 63,192,086 and 59,506,286 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	63,192		59,506
( us-gaap:CommonStockParOrStatedValuePerShare )	63192		59506
Additional paid in capital	16,678,930		12,879,982
( us-gaap:AdditionalPaidInCapital )	16678930		12879982
Retained deficit	(17,300,043	)	(14,515,214	)
( us-gaap:RetainedEarningsAccumulatedDeficit )	-17300043		-14515214
TOTAL STOCKHOLDERS’ EQUITY (DEFICIT)	(557,921	)	(1,575,726	)
( us-gaap:StockholdersEquity )	-557921		-1575726
TOTAL LIABILITIES AND STOCKHOLDERS’EQUITY (DEFICIT)	545,945		188,971
( us-gaap:LiabilitiesAndStockholdersEquity )	545945		188971

(End Statement - Balance Sheets (Unaudited))

Statement - Balance Sheets (Parenthetical)

Statement - Balance Sheets (Parenthetical) (USD $)
( us-gaap:StatementOfFinancialPositionAbstract )
	Sep. 30, 2015	Dec. 31, 2014







Common stock, par value $.001, shares authorized	100,000,000	100,000,000
( us-gaap:CommonStockSharesAuthorized )	100000000	100000000
Common stock, par value $.001, shares issued and outstanding	63,192,086	59,506,286
( us-gaap:CommonStockSharesIssued )	63192086	59506286

(End Statement - Balance Sheets (Parenthetical))

Statement - Statements of Operations (Unaudited)

Statement - Statements of Operations (Unaudited) (USD $)	3 Months Ended				9 Months Ended
( us-gaap:IncomeStatementAbstract )
	Sep. 30, 2015		Sep. 30, 2014		Sep. 30, 2015		Sep. 30, 2014







revenues	49,991		31,865		208,176		67,500
( us-gaap:Revenues )	49991		31865		208176		67500
cost of goods sold	49,991		31,865		208,176		67,500
( us-gaap:CostOfGoodsSold )	49991		31865		208176		67500
gross profit	�		�		�		�
( us-gaap:GrossProfit )
operating expenses
( us-gaap:OperatingExpensesAbstract )
Research and development	599,641		1,111,526		1,225,703		2,770,964
( us-gaap:ResearchAndDevelopmentExpense )	599641		1111526		1225703		2770964
Selling, general and administrative	330,695		466,874		1,555,793		2,118,973
( us-gaap:SellingGeneralAndAdministrativeExpense )	330695		466874		1555793		2118973
Depreciation expense	1,112		771		3,337		2,314
( us-gaap:Depreciation )	1112		771		3337		2314
Operating loss before other items and income tax	(931,448	)	(1,579,171	)	(2,784,833	)	(4,892,251	)
( us-gaap:OperatingIncomeLoss )	-931448		-1579171		-2784833		-4892251


Other INCOME/(EXPENSE)
( us-gaap:OtherOperatingIncomeExpenseNet )
iNTEREST INCOME	2		76		4		694
( us-gaap:InterestAndDividendIncomeOperating )	2		76		4		694
Income tax expense (benefit)	�		�		�		�
( us-gaap:IncomeTaxExpenseBenefit )
net loss availAble to common stockholders	(931,446	)	(1,579,095	)	(2,784,829	)	(4,891,557	)
( us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic )	-931446		-1579095		-2784829		-4891557
COMPREHENSIVE LOSS FOR THE PERIOD	(931,446	)	(1,579,095	)	(2,784,829	)	(4,891,557	)
( us-gaap:ComprehensiveIncomeNetOfTax )	-931446		-1579095		-2784829		-4891557
basic and diluted loss per common share	(0.01	)	(0.03	)	(0.05	)	(0.09	)
( us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare )	-0.01		-0.03		-0.05		-0.09
weighted average shares outstanding	61,735,634		58,005,199		60,176,839		56,776,286
( us-gaap:WeightedAverageBasicSharesOutstandingProForma )	61735634		58005199		60176839		56776286

(End Statement - Statements of Operations (Unaudited))

Disclosure - Basis Of Financial Statement Presentation

Disclosure - Basis Of Financial Statement Presentation (USD $)

9 Months Ended

( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )

Sep. 30, 2015

Basis Of Financial Statement Presentation

BASIS OF FINANCIAL STATEMENT PRESENTATION

The accompanying unaudited condensedconsolidated financial statements have been prepared by ArtVentive Medical Group, Inc. “the Company” pursuant to therules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally includedin financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omittedin accordance with such rules and regulations. The information furnished in the interim condensed financial statements includesnormal recurring adjustments and reflects all adjustments, which, in the opinion of management, are necessary for a fair presentationof such financial statements. Although management believes the disclosures and information presented are adequate to make the informationnot misleading, it is suggested that these interim condensed consolidated financial statements be read in conjunction with theCompany's audited financial statements and notes thereto included in its Form 10-K filed on March 31, 2015. Operating results forthe nine months ended September 30, 2015 are not necessarily indicative of the results to be expected for the fiscal year endedDecember 31, 2015.

( us-gaap:BasisOfAccounting )

(End Disclosure - Basis Of Financial Statement Presentation)

Disclosure - Organization

Disclosure - Organization (USD $)	9 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Sep. 30, 2015



Organization	2. ORGANIZATION ArtVentive Medical Group, Inc. (the“Company”), is a Nevada Corporation traded on the OTCQB (symbol AVTD). On January 9, 2010, the Company completed theacquisition of all of the assets of ArtVentive Medical Inc., a California company. The accounting and reporting policiesof the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscalyear end is December 31. The Company is a medical device corporation,focused on developing, manufacturing and marketing a family of Endoluminal Occlusion Devices (EOS^TM). Through its innovative,proprietary technology the Company has developed unique minimally invasive occlusion devices and procedures, bringing the currentinterventional, image guided techniques to a new level of sophistication, potentially resolving significant and unaddressed healthissues. The EOS device being developed by the Company targets a substantive market demand in several major clinical areas, includingwomen's health, peripheral and neurological vascular disorders, and interventional cardiology procedures. To date, the Company’s activitieshave been committed to the development of the EOS^TM, intellectual property, animal studies, human studies, patent filings,manufacturing, sales, marketing and implementing its regulatory strategy for clinical indications for European regulatory and FDAsubmissions and approval, corporate operations and the raising of equity capital. The Company conducted the requiredhuman clinical studies during 2011 achieving 100% clinical and procedural success, validating the safety and efficiency of theArtVentive EOS^TM device. On August 3, 2011, the Company incorporatedArtVentive Women’s Health Group, Inc., a wholly owned subsidiary of the Company. The Company received its CE Markcertification for the ArtVentive EOS™ Peripheral device on May 30, 2013, and implemented the planned EOS™ peripheraldevice transfer from Research and Development to commercialization, marketing, and distribution throughout Europe, simultaneousto making its FDA application. The Company received FDA approval for the ArtVentive EOS™ Peripheral device on December 3,2014. The Company filed additional patentapplications expanding its patent reach of the ArtVentive EOS™ device to 24 patents or patent applications.
( us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock )

(End Disclosure - Organization)

Disclosure - Significant Accounting Policies

Disclosure - Significant Accounting Policies (USD $)

9 Months Ended

( AccountingPoliciesAbstract )

Sep. 30, 2015

Significant Accounting Policies

3. SIGNIFICANT ACCOUNTING POLICIES

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the transactionsof the Company and its subsidiary.

All inter-company accounts and transactions have beeneliminated in consolidation.

USE OF ESTIMATES

The preparation of the Company’sfinancial statements in conformity with accounting principles generally accepted in the United States requires management to makeestimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilitiesat the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual resultscould differ from those estimates. The Company’s periodic filings with the Securities and Exchange Commission include, whereapplicable, disclosures of estimates, assumptions, uncertainties and markets that could affect the financial statements and futureoperations of the Company.

COMMON STOCK ISSUED FOR OTHER THAN CASH

Services purchased and other transactionssettled in the Company’s common stock and stock options are recorded at the estimated fair value of the stock issued andoptions granted if that value is more readily determinable than the fair value of the consideration received.

EARNINGS PER SHARE OF COMMON STOCK

In accordance with accounting guidancenow codified as FASB ASC Topic 260, “Earnings per Share,” basic earnings (loss) per share is computed by dividing netincome (loss) by weighted average number of shares of common stock outstanding during each period.

Diluted earnings (loss) per shareis computed by dividing net income (loss) by the weighted average number of shares of common stock, common stock equivalents andpotentially dilutive securities outstanding during the period.

The Company had the following potential common stock equivalentsat September 30, 2015:

Common stock warrants 3,700,000

Common stock options 330,000

Convertible notes payable 523,097

Total common stock equivalents 4,553,097

Since the Company reflected a netloss as of September 30, 2015 and 2014, the effect of considering any common stock equivalents, if outstanding, would have beenanti-dilutive. A separate computation of diluted earnings (loss) per share is not presented.

The following table sets forth the computation of earningsper share:

Sept. 30, 2015 Sept. 30, 2014

Net income (loss) $ (2,784,289) $ (4,891,557)

Weighted average common shares outstanding 60,176,83956,776,286

Net (loss) per share $ (0.05) $ (0.09)

PROPERTY AND EQUIPMENT

The Company records property and equipment at cost anduses straight-line depreciation methods.

	Estimated Useful Lives	September 30, 2015	December 31, 2014
Computer equipment Office furniture	5 years 7 years	$ 19,056 4,746	$ 13,207 4,746

Less accumulated depreciation		(8,804)	(5,467)

Net property and equipment		$ 14,998	$ 12,486

INVENTORY

The Company’s inventory isvalued at the lower of cost or market using the first-in, first-out (FIFO) method. As of September 30, 2015 and December 31, 2014,all inventory consisted of finished goods.

As the Company begins its transitionfrom the Research and Development phase to production, management has estimated the cost of units sold to be equal to the revenuegenerated on those units. Other direct cost that may be associated with the production of these units has been reflected in Researchand Development expenses.

FOREIGN CURRENCYTRANSLATIONS

The Company’s functionaland reporting currency is the US dollar. All transactions initiated in other currencies are translated into US dollars using theexchange rate prevailing on the date of transaction.

Monetary assets and liabilitiesdenominated in foreign currencies are translated into the US dollar at the rate of exchange in effect at the balance sheet date.Unrealized exchange gains and losses arising from such transactions are deferred until realization and are included as a separatecomponent of stockholders’ equity (deficit) as a component of other comprehensive income or loss. Upon realization, the amountdeferred is recognized in income in the period when it is realized.

CASH AND CASH EQUIVALENTS

Cash and cash equivalents consistprincipally of funds on hand, deposit with banks and liquid investment funds having maturity of three months or less at the timeof the purchase. The Company has no cash equivalents. The Company had funds on deposit of $53,005 at September 30, 2015.

REVENUE RECOGNITION

Revenue for the sale of goods inthe course of the ordinary activities is measured at the fair value of the consideration received or receivable, net of returns.Revenue for sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer,recovery of the consideration is probable, the associated costs and possible return of the goods can be estimated reliably, thereis no continuing involvement with the goods, and the amount of the revenue can be measured reliably.

CONCENTRATION OF RISK

Certain financial instruments, whichsubject the Company to concentration of credit risk, consist of cash. The Company maintains cash balances at financial institutionswhich, from time to time, may exceed Federal Deposit Insurance Corporation insured limits of $250,000. As of September 30, 2015and December 31, 2014, the Company had no deposits in excess of federally insured limits in its US bank. The Company has not experiencedany losses with regard to its bank accounts and believes it is not exposed to any risk of loss on its cash in bank accounts.

( us-gaap:SignificantAccountingPoliciesTextBlock )

(End Disclosure - Significant Accounting Policies)

Disclosure - Note Payable

Disclosure - Note Payable (USD $)

9 Months Ended

( DebtDisclosureAbstract )

Sep. 30, 2015

Note Payable

4. NOTE PAYABLE

On April 1, 2014, the Company borrowed $250,000 from an unrelatedparty and issued a note payable on or before December 31, 2014, with interest at 3% per annum. On December 31, 2014, the Companyand the lender executed an extension of the note, which is now due on or before December 31, 2017. The interest remains at 3%.The lender may convert all or part of the debt, including interest, into common stock of the Company at any time at the rate of$1 per share.

	September 30, 2015	December 31, 2014
Note payable to private party, with interest at 3.0%, with the balance, interest and principal, due December 31, 2017	$ 250,000	$ 250,000
Note payable to private party, with interest at 3.0%, with the balance, interest and principal, due December 31, 2017	250,000	250,000
Total	500,000	500,000
Less current maturities of long-term debt	-	-
Noncurrent maturities of long-term debt	$ 500,000	$ 500,000

Maturities on long-term debt are as follows:

2015	$ -
2016	-
2017	$ 500,000
	$ 500,000

( us-gaap:DebtDisclosureTextBlock )

(End Disclosure - Note Payable)

Disclosure - NOTE PAYABLE

Disclosure - NOTE PAYABLE (USD $)	9 Months Ended
( DebtDisclosureAbstract )
	Sep. 30, 2015



NOTE PAYABLE	5. SHARE CAPITAL Effective January 7, 2014, 400,000shares were issued in a private placement for the receipt of $400,000. Effective February 11, 2014,400,000 shares were issued in a private placement for the receipt of $400,000. Effective March 6, 2014, 300,000shares were issued in a private placement for the receipt of $300,000. Effective May 23, 2014, 100,000 shares wereissued in a private placement for the receipt of $100,000. Effective June 24, 2014, 1,000,000 shareswere issued in a private placement for the receipt of $1,000,000. Effective July 23, 2014, 500,000 shares wereissued in a private placement for the receipt of $500,000. Effective August 29, 2014, 250,000 shareswere issued in a private placement for the receipt of $250,000. Effective September 29, 2014, 150,000 shareswere issued in a private placement for the receipt of $150,000. Effective September 30, 2014, 100,000 shareswere issued in a private placement for the receipt of $100,000. Effective October 15, 2014, 100,000 shareswere issued in a private placement for the receipt of $100,000 Effective November 7, 2014, 80,000 shareswere issued in a private placement for the receipt of $80,000. Effective November 28, 2014, 70,000 shareswere issued in a private placement for the receipt of $70,000. Effective December 4, 2014, 250,000 shareswere issued in a private placement for the receipt of $250,000. Effective December 15, 2014, 250,000 shareswere issued in a private placement for the receipt of $250,000 Effective December 29, 2014, 250,000 shareswere issued in a private placement for the receipt of $250,000 Effective January 23, 2015, 250,000 shareswere issued in a private placement for the receipt of $250,000. Effective February 27, 2015, 150,000 shareswere issued in a private placement for the receipt of $150,000 Effective March 15, 2015, 100,000 shares wereissued in a private placement for the receipt of $100,000 Effective March 31, 2015, 150,000 shares wereissued in a private placement for the receipt of $150,000 Effective April 23, 2015, 150,000shares were issued in a private placement for the receipt of $150,000. Effective May 4, 2015, 100,000 shareswere issued in a private placement for the receipt of $100,000. Effective May 5, 2015, 960,800 shares wereissued for $1,070,800 of prior years' accrued issuance costs. Effective May 29, 2015, 500,000 shareswere issued in a private placement for the receipt of $500,000. Effective June 1, 2015, 500,000 shareswere issued in a private placement for the receipt of $500,000. Effective July 17, 2015, 200,000shares were issued in a private placement for the receipt of $200,000. Effective August 8, 2015, 50,000shares were issued in a private placement for the receipt of $50,000 on April 16, 2015. Effective August 27, 2015, 300,000shares were issued in a private placement for the receipt of $300,000. Effective September 28, 2015, 250,000shares were issued in a private placement for the receipt of $250,000.
( us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock )

(End Disclosure - NOTE PAYABLE)

Disclosure - Going Concern And Liquidity Considerations

Disclosure - Going Concern And Liquidity Considerations (USD $)	9 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Sep. 30, 2015



Going Concern And Liquidity Considerations	6. GOING CONCERN AND LIQUIDITYCONSIDERATIONS The accompanying financial statementshave been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realizationof assets and satisfaction of liabilities in the normal course of business. As of September 30, 2015, the Company has a negativeworking capital balance of $188,101 and an accumulated deficit of $17,300,043. The Company intends to fund operations through equityfinancing arrangements, which should be sufficient to fund its capital expenditures, working capital and other cash requirementsfor the next twelve months. The ability of the Company to implementits business plan is dependent upon, among other things, obtaining additional financing to continue operations, research and developmentand production of its product. The Company has a present offeringto shareholders for 15,000,000 shares, of which 11,118,000 has been subscribed to date. The Company continues to offer the remaining3,832,000 shares to those shareholders. With other potential future financing, management believes these initiatives alleviatethe substantial doubt regarding the Company’s ability to continue as a going concern.
( us-gaap:LiquidityDisclosureTextBlock )

(End Disclosure - Going Concern And Liquidity Considerations)

Disclosure - Recently Issued Accounting Pronouncements

Disclosure - Recently Issued Accounting Pronouncements (USD $)	9 Months Ended
( OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract )
	Sep. 30, 2015



Recently Issued Accounting Pronouncements	7. recentlyissued accounting pronouncements Accounting Standards Updates(“ASU”) ASU No. 2015-16 which contain technical corrections to existing guidance or affect guidance to specializedindustries or entities were recently issued. These updates have no current applicability to the Company or their effect on thefinancial statements would not have been significant.
( us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock )

(End Disclosure - Recently Issued Accounting Pronouncements)

Disclosure - Provision For Income Taxes

Disclosure - Provision For Income Taxes (USD $)

9 Months Ended

( IncomeTaxDisclosureAbstract )

Sep. 30, 2015

Provision For Income Taxes

8. provisionfor income taxes

The Company recognizes the taxeffects of transactions in the year in which such transactions enter into the determination of net income, regardless of when reportedfor tax purposes. Deferred taxes are provided in the financial statements under ASC Topic 740 to give effect to the resulting temporarydifferences which may arise from differences in the bases of fixed assets, depreciation methods, allowances, and start-up costsbased on the income taxes expected to be payable in future years. Minimal exploration stage deferred tax assets arising as a resultof net operating loss carry forwards have been offset completely by a valuation allowance due to the uncertainty of their utilizationin future periods. The Company adopted the provisions of ASC Topic 740 Accounting for Uncertainty in Income Taxes, on January23, 2007 (inception date). As a result of the implementation of ASC 740, the Company recognized no increase in the liability forunrecognized tax benefits.

Operating loss carry-forwards generatedduring the period of January 23, 2007 (date of inception), through September 30, 2015, of approximately $17.1 million, will beginto expire in 2027. Accordingly, deferred tax assets of approximately $7.1 million related to net operating loss carry-forwards,and approximately $215,000 related to stock-based compensation were offset by the valuation allowance in the same amount. For thenine months ended September 30, 2015 and 2014, the allowance increased by approximately $1,200,000 and $1,419,000, respectively.

The Company adopted the provisionsof FASB Interpretation No. 48 Accounting for Uncertainty in Income Taxes, on January 23, 2007. As a result of the implementationof Interpretation 48, the Company recognized no increase in the liability for unrecognized tax benefits.

The Company has no tax positionsat September 30, 2015, or December 31, 2014, for which the ultimate deductibility is highly certain but for which there is uncertaintyabout the timing of such deductibility.

The Company’s tax returnsfor the years ended December 31, 2014, 2013, 2012 and 2011 are open for examination under Federal Statute of Limitations and forthe years ended December 31, 2014, 2013 and 2012 under the State of California Statute of Limitations.

The Company recognizes interestaccrued related to unrecognized tax benefits in interest expense and penalties in operating expenses. The Company had no accrualsfor interest and penalties since inception.

Components of income tax benefitsare as follows:

Years Ended December 31,
2014	2013
$ -	$ -
-	-
-	-
-	-
-	-

( us-gaap:IncomeTaxDisclosureTextBlock )

(End Disclosure - Provision For Income Taxes)

Disclosure - Warrants and Options

Disclosure - Warrants and Options (USD $)

9 Months Ended

( OtherLiabilitiesDisclosureAbstract )

Sep. 30, 2015

Warrants and Options

9. Warrantsand options

Warrants:

During the fiscal year ended December31, 2014, the Company granted 4,200,000 warrants to purchase shares of Common Stock which all have a 1 year exercise term, of which3,700,000 remain outstanding at September 30, 2015. During the quarter ended September 30, 2015, 750,000 warrants were issued.The Company valued all warrants utilizing a Black-Scholes option pricing model and the fair value was recorded in additional paid-incapital.

The following is a summary of theCompany’s warrant activity:

	Warrants	Weighted Average Exercise Price
Exercisable – December 31, 2013	4,358,000	$ 1.50
Granted-2014	4,200,000	$ 1.50
Exercised-2014	-	-
Forfeited-2014	(4,358,000)	$ 1.50
Outstanding – December 31, 2014	4,200,000	$ 1.50
Exercisable – December 31, 2014	4,200,000	$ 1.50

	Warrants	Weighted Average Exercise Price
Granted-2015 (at September 30, 2015)	2,700,000	$ 1.50
Exercised-2015 (at September 30,2015)	-	-
Forfeited-2015 (at September 30, 2015)	(3,200,000)	$ 1.50
Outstanding – September 30, 2015	3,700,000	$ 1.50
Exercisable – September 30, 2015	3,700,000	$ 1.50

Warrants outstanding and exercisableat September 30, 2015 are as follows:

Warrants Outstanding				Warrants Exercisable
	Range of Exercise Price	Number Outstanding	Weighted Average Remaining Contractual Life (in Years)	Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$	1.50	100,000	0.04 years	$	1.50		100,000	$	1.50
$	1.50	80,000	0.10 years	$	1.50		80,000	$	1.50
$	1.50	70,000	0.16 years	$	1.50		70,000	$	1.50
$	1.50	250,000	0.17 years	$	1.50		250,000	$	1.50
$	1.50	250,000	0.21 years	$	1.50		250,000	$	1.50
$	1.50	250,000	0.25 years	$	1.50		250,000	$	1.50

$	1.50	250,000	0.31 years	$	1.50		250,000	$	1.50
$	1.50	150,000	0.41 years	$	1.50		150,000	$	1.50
$	1.50	100,000	0.45 years	$	1.50		100,000	$	1.50
$	1.50	150,000	0.50 years	$	1.50		150,000	$	1.50
$	1.50	50,000	0.54 years	$	1.50		50,000	$	1.50
$	1.50	150,000	0.56 years	$	1.50		150,000	$	1.50
$	1.50	100,000	0.59 years	$	1.50		100,000	$	1.50
$	1.50	500,000	0.65 years	$	1.50		500,000	$	1.50
$	1.50	500,000	0.67 years	$	1.50		500,000	$	1.50
$	1.50	200,000	0.79 years	$	1.50		200,000	$	1.50
$	1.50	300,000	0.91 years	$	1.50		300,000	$	1.50
$	1.50	250,000	0.99 years	$	1.50		250,000	$	1.50

Warrant activity is as follows:

Effective October 15 2014, 100,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective November 7, 2014, 80,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective November 28, 2014, 70,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective December 4, 2014, 250,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective December 15, 2014, 250,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective January 3, 2015, 250,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective January 23, 2015, 250,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective January 30, 2015, 150,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective March 15, 2015, 100,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective March 31, 2015, 150,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective April 16, 2015, 50,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective April 23, 2015, 150,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective May 4, 2015, 100,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective May 28, 2015, 500,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective June 1, 2015, 500,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective July 17, 2015, 200,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective August 27, 2015, 300,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Effective September 28, 2015, 250,000warrants were issued. The warrants allow the purchase of common shares at an exercise price of $1.50. There is no vesting period,and the warrants expire in 1 year

Stock Options:

During the period that the optionswere issued, the Company had no public trading activity for the Company’s common stock. However, the Company sold in privatetransactions shares at $1.00 per share. In order to value the Company’s options, the Company chose to use the minimum valuemethod, even though the Company is a public company since there was no measurable trading activity. The fair value of the optionswas recorded in additional paid-in capital.

Options outstanding and exercisableat September 30, 2015 are as follows:

	Options	Weighted Average Exercise Price
Outstanding – December 31, 2013	305,000	$ 0.836
Exercisable – December 31, 2013	105,000	$ 0.524
Granted-2014	-	$ -
Exercised-2014	-	-
Forfeited-2014	-	-
Outstanding – December 31, 2014	305,000	$ 0.836
Exercisable – December 31, 2014	155,000	$ 0.678
	Options	Weighted Average Exercise Price
Granted-2015 (at September 30, 2015)	275,000	$ 1.00
Exercised-2015 (at September 30, 2015)	(50,000)	$ 0.001
Forfeited-2015 (at September 30, 2015)	(200,000)	$ 1.00
Outstanding – September 30, 2015	330,000	$ 1.00
Exercisable – September 30, 2015	230,000	$ 1.00

Options outstandingand exercisable at September 30, 2015 are as follows:

Options Outstanding							Options Exercisable
	Range of Exercise Price		Number Outstanding		Remaining Contractual Life (in Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Exercise Price
$		1.00		35,000		2.34 years	$	1.00		35,000		$	1.00
$		1.00		50,000		0.24 years	$	1.00		50,000		$	1.00
$		1.00		10,000		2.42 years	$	1.00		10,000		$	1.00
$		1.00		10,000		3.24 years	$	1.00		10,000		$	1.00
$		1.00		10,000		9.32 years	$	1.00		10,000		$	1.00
$		1.00		100,000		9.58 years	$	1.00		100,000		$	1.00
$		1.00		15,000		9.91 years	$	1.00		15,000		$	1.00
$		1.00		100,000		9.98 years	$	1.00		-		$	1.00

Stock option activity is as follows:

Effective November 2, 2010 theBoard of Directors of the Company granted 50,000 non-statutory stock options to a former consultant at an exercise price of $.001per share with the vesting date of November 2, 2013 and an expiration date of November 2, 2016. These options were exercised onAugust 7, 2015.

Effective February 1, 2013 theBoard of Directors of the Company granted 20,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of February 1, 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013 theBoard of Directors of the Company granted 5,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.

Effective February 1, 2013 theBoard of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of February 1 2013 and an expiration date of February 1, 2018.

Effective March 1, 2013 the Boardof Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 pershare with the vesting date of March 1, 2013 and an expiration date of March 1, 2018.

Effective December 1, 2013 theBoard of Directors of the Company granted 200,000 non-statutory incentive stock options to a current employee at an exercise priceof $1.00 per share with 50,000 of the shares vested on January 1, 2015 and the additional 75% of shares exercisable on each ofthe next succeeding three anniversaries of January 1. The 50,000 vested stock options remain outstanding, while the 150,000 non-vestedoptions were forfeited through a voluntary resignation on September 4, 2015.

Effective December 27, 2013 theBoard of Directors of the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00per share with the vesting date of December 27, 2013 and an expiration date of December 27, 2018.

Effective January 1, 2015 theBoard of Directors of the Company granted 50,000 non-statutory incentive stock options to a current employee at an exercise priceof $1.00 per share with 25% of the shares vested on January 1, 2016 and an additional 25% of shares exercisable on each of thenext succeeding three anniversaries of January 1. The 50,000 non-vested options were forfeited through a voluntary resignationon September 4, 2015.

Effective January 23, 2015 the Board of Directorsof the Company granted 10,000 non-statutory stock options to a current consultant at an exercise price of $1.00 per share withthe vesting date of January 23, 2015 and an expiration date of January 23, 2025.

Effective April 30, 2015 the Board of Directors ofthe Company granted 100,000 non-qualified stock options to a current consultant at an exercise price of $1.00 per share with thevesting date of April 30, 2015 and an expiration date of April 30, 2025

Effective August 28, 2015, theBoard of Directors of the Company granted 15,000 non-qualified stock options to a current board advisor at an exercise price of$1.00 per share with the vesting date of August 31, 2105, and an expiration date of August 31, 2025

Effective September 22, 2015,the Board of Directors of the Company granted 100,000 non-qualified stock options to a current consultant at an exercise priceof $1.00 per share with 25% of the shares vesting on September 22, 2016 and an additional 25% of shares exercisable on each ofthe next succeeding three anniversaries of September 22, with the full portion exercisable on and after September 22, 2019 andan expiration date of September 22, 2025.

( us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock )

(End Disclosure - Warrants and Options)

Disclosure - Subsequent Events

Disclosure - Subsequent Events (USD $)	9 Months Ended
( SubsequentEventsAbstract )
	Sep. 30, 2015



Subsequent Events	10.SUBSEQUENT EVENTS The Company evaluated all events or transactions that occurredafter September 30, 2015, up through the date these consolidated financial statements were issued. Effective October 28, 2015, the Company issued 150,000 sharesin a private placement for a receipt of $150,000.
( us-gaap:SubsequentEventsTextBlock )

(End Disclosure - Subsequent Events)

Disclosure - Significant Accounting Policies (Policies)

Disclosure - Significant Accounting Policies (Policies) (USD $)

9 Months Ended

( AccountingPoliciesAbstract )

Sep. 30, 2015

Principles of Consolidation

PRINCIPLES OF CONSOLIDATION

The consolidated financial statements include the transactionsof the Company and its subsidiary.

All inter-company accounts and transactions have beeneliminated in consolidation.

( us-gaap:ConsolidationPolicyTextBlock )

USE OF ESTIMATES

USE OF ESTIMATES

( us-gaap:UseOfEstimates )

COMMON STOCK ISSUED FOR OTHER THAN CASH

COMMON STOCK ISSUED FOR OTHER THAN CASH

( us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy )

EARNINGS PER SHARE OF COMMON STOCK

EARNINGS PER SHARE OF COMMON STOCK

The Company had the following potential common stock equivalentsat September 30, 2015:

Common stock warrants 3,700,000

Common stock options 330,000

Convertible notes payable 523,097

Total common stock equivalents 4,553,097

The following table sets forth the computation of earningsper share:

Sept. 30, 2015 Sept. 30, 2014

Net income (loss) $ (2,784,289) $ (4,891,557)

Weighted average common shares outstanding 60,176,83956,776,286

Net (loss) per share $ (0.05) $ (0.09)

( us-gaap:EarningsPerSharePolicyTextBlock )

Property and Equipment

PROPERTY AND EQUIPMENT

The Company records property and equipment at cost anduses straight-line depreciation methods.

	Estimated Useful Lives	September 30, 2015	December 31, 2014
Computer equipment Office furniture	5 years 7 years	$ 19,056 4,746	$ 13,207 4,746

Less accumulated depreciation		(8,804)	(5,467)

Net property and equipment		$ 14,998	$ 12,486

( us-gaap:PropertyPlantAndEquipmentPolicyTextBlock )

INVENTORY

INVENTORY

( us-gaap:InventoryPolicyTextBlock )

FOREIGN CURRENCY TRANSLATIONS

FOREIGN CURRENCYTRANSLATIONS

( us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock )

CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS

( us-gaap:CashAndCashEquivalentsPolicyTextBlock )

REVENUE RECOGNITION

REVENUE RECOGNITION

( us-gaap:RevenueRecognitionPolicyTextBlock )

CONCENTRATION OF RISK

CONCENTRATION OF RISK

( us-gaap:ConcentrationRiskDisclosureTextBlock )

(End Disclosure - Significant Accounting Policies (Policies))

Disclosure - Note Payable (Tables)

Disclosure - Note Payable (Tables) (USD $)

9 Months Ended

( DebtDisclosureAbstract )

Sep. 30, 2015

Schedule of Debt

	September 30, 2015	December 31, 2014
Note payable to private party, with interest at 3.0%, with the balance, interest and principal, due December 31, 2017	$ 250,000	$ 250,000
Note payable to private party, with interest at 3.0%, with the balance, interest and principal, due December 31, 2017	250,000	250,000
Total	500,000	500,000
Less current maturities of long-term debt	-	-
Noncurrent maturities of long-term debt	$ 500,000	$ 500,000

Maturities on long-term debt are as follows:

2015	$ -
2016	-
2017	$ 500,000
	$ 500,000

( us-gaap:ScheduleOfDebtInstrumentsTextBlock )

(End Disclosure - Note Payable (Tables))

Disclosure - Note Payable - Schedule of Debt (Details)

Disclosure - Note Payable - Schedule of Debt (Details) (USD $)
( DebtDisclosureAbstract )
	Sep. 30, 2015	Dec. 31, 2014



Note payable to private party, with interest at 3.0%, with the balance, interest and principal, due December 31, 2017	500,000	500,000
( us-gaap:NotesPayableCurrent )	500000	500000
Total	500,000	500,000
( us-gaap:DebtCurrent )	500000	500000
Less current maturities of long-term debt	�	�
( us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost )
Noncurrent maturities of long-term debt	500,000	500,000
( us-gaap:OtherLongTermDebtNoncurrent )	500000	500000

(End Disclosure - Note Payable - Schedule of Debt (Details))

Contexts

ID	Period	CIK
From2015-01-01to2015-09-30	2015-01-01 - 2015-09-30	0001405249
AsOf2015-11-03	2015-11-03	0001405249
AsOf2015-09-30	2015-09-30	0001405249
AsOf2014-12-31	2014-12-31	0001405249
From2015-07-01to2015-09-30	2015-07-01 - 2015-09-30	0001405249
From2014-07-01to2014-09-30	2014-07-01 - 2014-09-30	0001405249
From2014-01-01to2014-09-30	2014-01-01 - 2014-09-30	0001405249

(End Contexts)

Elements

Element		Data Type

AccountingPoliciesAbstract		xbrli:stringItemType	Duration	—

DebtDisclosureAbstract		xbrli:stringItemType	Duration	—

IncomeTaxDisclosureAbstract		xbrli:stringItemType	Duration	—

OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract		xbrli:stringItemType	Duration	—

OtherLiabilitiesDisclosureAbstract		xbrli:stringItemType	Duration	—

SubsequentEventsAbstract		xbrli:stringItemType	Duration	—

custom:DocumentAndEntityInformationAbstract		xbrli:stringItemType	Duration	—	Yes (Auto)

dei:AmendmentFlag		xbrli:booleanItemType	Duration	—
	If the value is true, then the document is an amendment to previously-filed/accepted document.
dei:CurrentFiscalYearEndDate		xbrli:gMonthDayItemType	Duration	—
	End date of current fiscal year in the format --MM-DD.
dei:DocumentFiscalPeriodFocus		dei:fiscalPeriodItemType	Duration	—
	This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
dei:DocumentFiscalYearFocus		xbrli:gYearItemType	Duration	—
	This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
dei:DocumentPeriodEndDate		xbrli:dateItemType	Duration	—
	The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
dei:DocumentType		dei:submissionTypeItemType	Duration	—
	The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
dei:EntityCentralIndexKey		dei:centralIndexKeyItemType	Duration	—
	A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
dei:EntityCommonStockSharesOutstanding		xbrli:sharesItemType	Instant	—
	Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
dei:EntityCurrentReportingStatus		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityFilerCategory		dei:filerCategoryItemType	Duration	—
	Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
dei:EntityPublicFloat		xbrli:monetaryItemType	Instant	Credit
	State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.
dei:EntityRegistrantName		xbrli:normalizedStringItemType	Duration	—
	The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
dei:EntityVoluntaryFilers		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
dei:EntityWellKnownSeasonedIssuer		dei:yesNoItemType	Duration	—
	Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
us-gaap:AccountsPayableCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccountsReceivableNet		xbrli:monetaryItemType	Instant	Debit
	For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
us-gaap:AccruedLiabilitiesCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccruedLiabilitiesCurrentAndNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
us-gaap:AccruedPayrollTaxesCurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		xbrli:monetaryItemType	Instant	Credit
	Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
us-gaap:AdditionalPaidInCapital		xbrli:monetaryItemType	Instant	Credit
	Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
us-gaap:Assets		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsAbstract		xbrli:stringItemType	Duration	—

us-gaap:AssetsCurrent		xbrli:monetaryItemType	Instant	Debit
	Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
us-gaap:AssetsCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost		xbrli:monetaryItemType	Instant	Debit
	Amount after adjustments of available-for-sale debt securities at cost, maturing in the sixth fiscal year through the tenth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.
us-gaap:BasisOfAccounting		nonnum:textBlockItemType	Duration	—
	The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
us-gaap:CashAndCashEquivalentsAtCarryingValue		xbrli:monetaryItemType	Instant	Debit
	Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
us-gaap:CashAndCashEquivalentsPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
us-gaap:CommonStockParOrStatedValuePerShare		num:perShareItemType	Instant	—
	Face amount or stated value per share of common stock.
us-gaap:CommonStockSharesAuthorized		xbrli:sharesItemType	Instant	—
	The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
us-gaap:CommonStockSharesIssued		xbrli:sharesItemType	Instant	—
	Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
us-gaap:ComprehensiveIncomeNetOfTax		xbrli:monetaryItemType	Duration	Credit
	Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
us-gaap:ConcentrationRiskDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.
us-gaap:ConsolidationPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
us-gaap:CostOfGoodsSold		xbrli:monetaryItemType	Duration	Debit
	Total costs related to goods produced and sold during the reporting period.
us-gaap:DebtAndCapitalLeasesDisclosuresTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for debt and capital lease obligations can be reported. Information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. Also includes descriptions and amounts of capital leasing arrangements that consist of direct financing, sales type and leveraged leases. Disclosure may include the effect on the balance sheet and the income statement resulting from a change in lease classification for leases tha
us-gaap:DebtCurrent		xbrli:monetaryItemType	Instant	Credit
	Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.
us-gaap:DebtDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
us-gaap:Deposits		xbrli:monetaryItemType	Instant	Credit
	The aggregate of all deposit liabilities held by the entity, including foreign and domestic, interest and noninterest bearing; may include demand deposits, saving deposits, Negotiable Order of Withdrawal (NOW) and time deposits among others.
us-gaap:Depreciation		xbrli:monetaryItemType	Duration	Debit
	The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
us-gaap:EarningsPerSharePolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
us-gaap:EquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
us-gaap:GrossProfit		xbrli:monetaryItemType	Duration	Credit
	Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare		num:perShareItemType	Duration	—
	The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.
us-gaap:IncomeStatementAbstract		xbrli:stringItemType	Duration	—

us-gaap:IncomeTaxDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
us-gaap:IncomeTaxExpenseBenefit		xbrli:monetaryItemType	Duration	Debit
	Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
us-gaap:InterestAndDividendIncomeOperating		xbrli:monetaryItemType	Duration	Credit
	Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.
us-gaap:InventoryGross		xbrli:monetaryItemType	Instant	Debit
	Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
us-gaap:InventoryPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.
us-gaap:LiabilitiesAndStockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
us-gaap:LiabilitiesAndStockholdersEquityAbstract		xbrli:stringItemType	Duration	—

us-gaap:LiabilitiesCurrent		xbrli:monetaryItemType	Instant	Credit
	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
us-gaap:LiabilitiesCurrentAbstract		xbrli:stringItemType	Duration	—

us-gaap:LiquidityDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. If management's plans alleviate the substantial doubt about the entity's ability to continue as a going concern, disclosure of the principal conditions and events that initially raised the substa
us-gaap:LongTermDebtAbstract		xbrli:stringItemType	Duration	—

us-gaap:LongTermDebtNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying amount of long-term debt, net of unamortized discount or premium, excluding amounts to be repaid within one year or the normal operating cycle, if longer (current maturities). Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic		xbrli:monetaryItemType	Duration	Credit
	Net income after adjustments for dividends on preferred stock (declared in the period) and/or cumulative preferred stock (accumulated for the period).
us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
us-gaap:NotesPayable		xbrli:monetaryItemType	Instant	Credit
	Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
us-gaap:NotesPayableCurrent		xbrli:monetaryItemType	Instant	Credit
	Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
us-gaap:OperatingExpensesAbstract		xbrli:stringItemType	Duration	—

us-gaap:OperatingIncomeLoss		xbrli:monetaryItemType	Duration	Credit
	The net result for the period of deducting operating expenses from operating revenues.
us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.
us-gaap:OtherAssets		xbrli:monetaryItemType	Instant	Debit
	The aggregate carrying amounts, as of the balance sheet date, of assets not separately disclosed in the balance sheet.
us-gaap:OtherAssetsAbstract		xbrli:stringItemType	Duration	—

us-gaap:OtherLongTermDebtNoncurrent		xbrli:monetaryItemType	Instant	Credit
	Carrying value as of the balance sheet date of debt not otherwise defined (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
us-gaap:OtherOperatingIncomeExpenseNet		xbrli:monetaryItemType	Duration	Credit
	The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.
us-gaap:PrepaidExpenseCurrent		xbrli:monetaryItemType	Instant	Debit
	Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
us-gaap:PropertyPlantAndEquipmentAbstract		xbrli:stringItemType	Duration	—

us-gaap:PropertyPlantAndEquipmentNet		xbrli:monetaryItemType	Instant	Debit
	Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
us-gaap:PropertyPlantAndEquipmentOther		xbrli:monetaryItemType	Instant	Debit
	Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.
us-gaap:PropertyPlantAndEquipmentPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.
us-gaap:ResearchAndDevelopmentExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
us-gaap:RetainedEarningsAccumulatedDeficit		xbrli:monetaryItemType	Instant	Credit
	The cumulative amount of the reporting entity's undistributed earnings or deficit.
us-gaap:RevenueRecognitionPolicyTextBlock		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
us-gaap:Revenues		xbrli:monetaryItemType	Duration	Credit
	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
us-gaap:ScheduleOfDebtInstrumentsTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock		nonnum:textBlockItemType	Duration	—
	Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
us-gaap:SellingGeneralAndAdministrativeExpense		xbrli:monetaryItemType	Duration	Debit
	The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
us-gaap:SignificantAccountingPoliciesTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for all significant accounting policies of the reporting entity.
us-gaap:StatementOfFinancialPositionAbstract		xbrli:stringItemType	Duration	—

us-gaap:StockholdersEquity		xbrli:monetaryItemType	Instant	Credit
	Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.
us-gaap:SubsequentEventsTextBlock		nonnum:textBlockItemType	Duration	—
	The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
us-gaap:UseOfEstimates		nonnum:textBlockItemType	Duration	—
	Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
us-gaap:WeightedAverageBasicSharesOutstandingProForma		xbrli:sharesItemType	Duration	—
	The weighted average number of shares (units) outstanding in the calculation of pro forma basic earnings per share (earnings per unit), which is commonly presented in initial public offerings based on the terms of the offering.
Total Elements					96
Total Non-Abstract Elements					78
Total Extension Elements					1
Percent Extended					1%
Percent Extended (excluding abstracts)					0%

(End Elements)